144 related articles for article (PubMed ID: 33044358)
1. Effect of Ketamine on Rumination in Treatment-Resistant Depressive Patients.
Vidal S; Jermann F; Aubry JM; Richard-Lepouriel H; Kosel M
J Clin Psychopharmacol; 2020; 40(6):607-610. PubMed ID: 33044358
[TBL] [Abstract][Full Text] [Related]
2. Efficacy and Safety of a Rapid Intravenous Injection of Ketamine 0.5 mg/kg in Treatment-Resistant Major Depression: An Open 4-Week Longitudinal Study.
Vidal S; Gex-Fabry M; Bancila V; Michalopoulos G; Warrot D; Jermann F; Dayer A; Sterpenich V; Schwartz S; Vutskits L; Khan N; Aubry JM; Kosel M
J Clin Psychopharmacol; 2018 Dec; 38(6):590-597. PubMed ID: 30346333
[TBL] [Abstract][Full Text] [Related]
3. Ketamine infusions for treatment resistant depression: a series of 28 patients treated weekly or twice weekly in an ECT clinic.
Diamond PR; Farmery AD; Atkinson S; Haldar J; Williams N; Cowen PJ; Geddes JR; McShane R
J Psychopharmacol; 2014 Jun; 28(6):536-44. PubMed ID: 24699062
[TBL] [Abstract][Full Text] [Related]
4. Metabolic Syndrome Rather Than Body Mass Index Is Associated With Treatment Response to Ketamine Infusions.
Dale RM; Bryant KA; Thompson NR
J Clin Psychopharmacol; 2020; 40(1):75-79. PubMed ID: 31834094
[TBL] [Abstract][Full Text] [Related]
5. Ketamine and Monoamine Oxidase Inhibitor Combination: Utility, Safety, Efficacy?
Bottemanne H; Bonnard E; Claret A; Petit AC; Gaillard R; Fossati P
J Clin Psychopharmacol; 2020; 40(6):636-638. PubMed ID: 33009225
[No Abstract] [Full Text] [Related]
6. Rapid inflammation modulation and antidepressant efficacy of a low-dose ketamine infusion in treatment-resistant depression: A randomized, double-blind control study.
Chen MH; Li CT; Lin WC; Hong CJ; Tu PC; Bai YM; Cheng CM; Su TP
Psychiatry Res; 2018 Nov; 269():207-211. PubMed ID: 30153598
[TBL] [Abstract][Full Text] [Related]
7. Neurocognitive effects of ketamine and association with antidepressant response in individuals with treatment-resistant depression: a randomized controlled trial.
Murrough JW; Burdick KE; Levitch CF; Perez AM; Brallier JW; Chang LC; Foulkes A; Charney DS; Mathew SJ; Iosifescu DV
Neuropsychopharmacology; 2015 Mar; 40(5):1084-90. PubMed ID: 25374095
[TBL] [Abstract][Full Text] [Related]
8. Neurocognitive effects of six ketamine infusions and the association with antidepressant response in patients with unipolar and bipolar depression.
Zhou Y; Zheng W; Liu W; Wang C; Zhan Y; Li H; Chen L; Li M; Ning Y
J Psychopharmacol; 2018 Oct; 32(10):1118-1126. PubMed ID: 30260273
[TBL] [Abstract][Full Text] [Related]
9. Cognitive function of patients with treatment-resistant depression after a single low dose of ketamine infusion.
Chen MH; Li CT; Lin WC; Hong CJ; Tu PC; Bai YM; Cheng CM; Su TP
J Affect Disord; 2018 Dec; 241():1-7. PubMed ID: 30081380
[TBL] [Abstract][Full Text] [Related]
10. Ketamine augmentation for outpatients with treatment-resistant depression: Preliminary evidence for two-step intravenous dose escalation.
Cusin C; Ionescu DF; Pavone KJ; Akeju O; Cassano P; Taylor N; Eikermann M; Durham K; Swee MB; Chang T; Dording C; Soskin D; Kelley J; Mischoulon D; Brown EN; Fava M
Aust N Z J Psychiatry; 2017 Jan; 51(1):55-64. PubMed ID: 26893373
[TBL] [Abstract][Full Text] [Related]
11. Dissociating the Clinical Role and Economic Value of Intranasal Esketamine.
Dadiomov D
J Manag Care Spec Pharm; 2020 Jan; 26(1):20-22. PubMed ID: 31880233
[TBL] [Abstract][Full Text] [Related]
12. Rapid and longer-term antidepressant effects of repeated ketamine infusions in treatment-resistant major depression.
Murrough JW; Perez AM; Pillemer S; Stern J; Parides MK; aan het Rot M; Collins KA; Mathew SJ; Charney DS; Iosifescu DV
Biol Psychiatry; 2013 Aug; 74(4):250-6. PubMed ID: 22840761
[TBL] [Abstract][Full Text] [Related]
13. Switching to Intranasal Esketamine Maintains the Antidepressant Response to Intravenous Racemic Ketamine Administration: A Case Series of 10 Patients.
Banov MD; Landrum RE; Moore MB; Szabo ST
J Clin Psychopharmacol; 2021 Sep-Oct 01; 41(5):594-599. PubMed ID: 34411009
[TBL] [Abstract][Full Text] [Related]
14. Efficacy of low-dose ketamine infusion in anxious vs nonanxious depression: revisiting the Adjunctive Ketamine Study of Taiwanese Patients with Treatment-Resistant Depression.
Chen MH; Lin WC; Wu HJ; Bai YM; Li CT; Tsai SJ; Hong CJ; Tu PC; Cheng CM; Su TP
CNS Spectr; 2021 Aug; 26(4):362-367. PubMed ID: 32419678
[TBL] [Abstract][Full Text] [Related]
15. The effects of low-dose ketamine on the prefrontal cortex and amygdala in treatment-resistant depression: A randomized controlled study.
Li CT; Chen MH; Lin WC; Hong CJ; Yang BH; Liu RS; Tu PC; Su TP
Hum Brain Mapp; 2016 Mar; 37(3):1080-90. PubMed ID: 26821769
[TBL] [Abstract][Full Text] [Related]
16. The Concurrent Treatment With Intravenous Ketamine and an Irreversible Monoamine Oxidase Inhibitor for Treatment-Resistant Depression Without Hypertensive Crises.
Wang JCC; Swainson J
J Clin Psychopharmacol; 2020; 40(5):515-517. PubMed ID: 32740556
[No Abstract] [Full Text] [Related]
17. Neurocognitive effects of subanesthetic serial ketamine infusions in treatment resistant depression.
Zavaliangos-Petropulu A; McClintock SM; Khalil J; Joshi SH; Taraku B; Al-Sharif NB; Espinoza RT; Narr KL
J Affect Disord; 2023 Jul; 333():161-171. PubMed ID: 37060953
[TBL] [Abstract][Full Text] [Related]
18. Serum BDNF as a peripheral biomarker of treatment-resistant depression and the rapid antidepressant response: A comparison of ketamine and ECT.
Allen AP; Naughton M; Dowling J; Walsh A; Ismail F; Shorten G; Scott L; McLoughlin DM; Cryan JF; Dinan TG; Clarke G
J Affect Disord; 2015 Nov; 186():306-11. PubMed ID: 26275358
[TBL] [Abstract][Full Text] [Related]
19. Rapid effectiveness of intravenous ketamine for ultraresistant depression in a clinical setting and evidence for baseline anhedonia and bipolarity as clinical predictors of effectiveness.
Thomas RK; Baker G; Lind J; Dursun S
J Psychopharmacol; 2018 Oct; 32(10):1110-1117. PubMed ID: 30182797
[TBL] [Abstract][Full Text] [Related]
20. Intravenous ketamine for treatment-resistant major depressive disorder.
Covvey JR; Crawford AN; Lowe DK
Ann Pharmacother; 2012 Jan; 46(1):117-23. PubMed ID: 22190250
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
